Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial-Reference-Cited by-同舟云学术

Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

Published:2017-03 Issue:3 Volume:28 Page:497-504
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Loibl S.,Jackisch C.,Schneeweiss A.,Schmatloch S.,Aktas B.,Denkert C.,Wiebringhaus H.,Kümmel S.,Warm M.,Paepke S.,Just M.,Hanusch C.,Hackmann J.,Blohmer J.-U.,Clemens M.,Dan Costa S.,Gerber B.,Engels K.,Nekljudova V.,von Minckwitz G.,Untch M.

Funder

GBG Forschungs GmbH with financial support from Celgene and Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/3/497/13789881/mdw610.pdf

Reference22 articles.

1. Role of HER2 gene overexpression in breast carcinoma;Menard;J Cell Physiol,2000

2. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer;Piccart-Gebhart;N Engl J Med,2005

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001